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A chronic wound is a problem often encountered in medical care, especially in areas that 
do not have adequate health facilities. Several factors causing the injury are mechanical, 
chemical, electrical, or heat. Chronic inflammation and bacterial infections are two 
significant factors that affect the process of wound chronicity. Mitomycin-C (MMC) 
is widely used as intravenous, oral, or topical anti-cancer drug. Mitomycin-C that is 
topically administration to an injury can cause cross-linking and decrease or stop the DNA 
transcription process lead the injury will not reach the healing phase. Mitomycin-C works 
as an inhibitor of fibroblast proliferation that can inhibit wound healing process. This study 
aimed to investigate the effect of topical MMC administration in chronic wound animals 
model. Eight female Wistar rats aged 70 to 90 days and weighing between 300 to 350g 
were used in this study. Wound model was made in the back area with a diameter of 
approximately 2 cm. Rats were then divided into 2 groups. The first group as treatment 
group which the wound rats were compressed using sterile gauze moistened with 0.5 
mg/mL of MMC for five min and rinsed with 10 mL of saline solution. The second group 
as control which the wound rats were compressed by using sterile gauze moistened with 
saline for 5 minutes. On day 3, 5, and 15, the wound profiles were observed consisting 
of wound diameter, necrosis, and consistency. The rat wound after MMC administration 
showed a slower decrease in diameter, fewer scar tissue formation, and development of 
necrotic tissue. In addition, the rat wound appeared as brownish-black, dry, thick chronic 
wounds and took longer to heal compared to those saline control. In conclusion, MMC 
administration inhibits the wound healing process on rat surgical wound model. 
ABSTRAK
Luka kronis merupakan suatu masalah yang sering dihadapi terutama di daerah dengan 
fasilitas kesehatan yang tidak memadai. Faktor penyebab terjadinya luka adalah mekanik, 
kimia, listrik, atau panas. Inflamasi kronik dan infeksi bakteri merupakan dua faktor 
utama yang mempengaruhi proses kronisitas luka. Mitomisin-C (MMC) merupakan 
sediaan intravena, oral, dan topikal yang banyak digunakan pada keganasan. Pemberian 
MMC topikal pada luka dapat menyebabkan pertautan silang dan menurunkan atau 
menghentikan proses transkripsi DNA sehingga dapat menghambat penyembuhan luka. 
Mitomisin bertindak  sebagai penghambat proliferasi fibroblast yang dapat menghambat 
penyembuhan luka. Penelitian ini bertujuan mengkaji efek pemberian MMC topical pada 
model hewan luka kronis. Delapan ekor tikus Wistar betina umur 70 hingga 90 hari, 
dengan berat antara 300 sampai 350g digunakan dalam penelitian ini. Luka dibuat pada 
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daerah punggung yang bebas rambut dengan ukuran diameter sekitar 2 cm. Tikus dibagi 
menjadi dua kelompok secara acak. Kelompok pertama sebagai kelompok perlakuan 
dikompres dengan kasa steril yang dibasahi MMC 0,5 mg/mL selama 5 menit kemudian 
dibilas dengan larutan salin 10 mL. Kelompok kedua sebagai kelompok kontrol dikompres 
dengan kasa steril yang dibasahi dengan salin saja selama 5 menit. Pada hari ke-3, 5, dan 
15 diamati profil luka tikus yang meliputi diameter luka, nekrosis, dan konsistensinya. 
Luka tikus setelah pemberian MMC menunjukkan penurunan diameter luka lebih lambat, 
pembentukan jaringan parut lebih sedikit dan terjadinya pembentukan jaringan nekrosis. 
Selain itu luka tampak berwarna lebih hitam kecoklatan, kering dan tebal dibandingkan 
kelompok kontrol. Dapat disimpulkan, pemberian MMC menghambat proses penyembuhan 
luka pada tikus.  
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INTRODUCTION
Chronic wounds are common medical 
problems, especially in areas where there are 
not adequate health facilities. Some factors 
that cause injury are mechanical, chemical, 
electrical, or heat. The wound healing process 
in the skin is a complicated cellular process, 
involving keratinocytes, fibroblasts, blood 
vessels, endothelial cells, and immune cells. 
Chronic injuries begin with acute onset 
injuries. Chronic wounds do not typically go 
beyond the initial stage of inflammation. An 
acute injury may become a chronic injury if 
there is no development in the wound healing 
process through hemostasis, inflammation, 
proliferation, and tissue maturation. The acute 
injury becomes chronic injury if it fails to 
improve within four weeks and does not show 
wound healing within eight weeks. Chronic 
inflammation and bacterial infection are two 
major causes that affect the chronicity of a 
wound.1-3 The ability to recognize chronic 
wounds by health care workers is essential, 
so that wound treatment is more appropriate, 
making wound healing faster and reducing 
wound care costs.
Mitomycin-C (MMC) is an anti-proli-
ferative agent that inhibits DNA synthesis. It is 
widely used as an intravenous, oral, or topical 
anti-cancer drug. Mitomycin-C is given 
topically on the wound to form crosslinks and 
stop the DNA transcription process so that the 
wound will not undergo the healing process. 
Topical application of MMC to scar tissue will 
act as aninhibitor of proliferative fibroblast, 
thus inhibits wound healing.4-6
Mitomycin-C has a broad-spectrum effect 
in inhibiting the proliferation of many cell 
types, and when used topically, the biological 
effect is affected by the concentration and 
duration of exposure. Larger concentration 
and longer duration of exposure result in 
greater biological effects. Its clinical use 
in inhibiting scar tissue formation has been 
extensively studied. The rats are often used in 
animal model of wound healing studies, but 
there are limitations involving the anatomical 
differences in human skin and rats, the wound 
healing process and the immune system. 
Regarding the anatomy, rats have denser 
hair follicles and thinner dermis layers than 
the human skin. It is also showed that the rat 
skin heals through contractions, causing the 
edges of the wound to be closer to each other, 
forming bag zippers, and re-epithelization. 
In contrast, human skin heals the wound by 
re-epithelization only, where keratinocytes 
accumulate on the granulation tissue to cover 
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the wound. With these differences, the study 
using rats are ideal for wound healing model.6-7 
This preliminary study aimed to investigate 
the effect of topical MMC administration in 
chronic wound animals model. 
MATERIALS AND METHODS
Animal model
Eight female Wistar rats aged 70 to 90 
days, weighing between 300 and 350 g were 
used in this study. The animals were kept in 
separate cages in the Integrated Research 
and Testing Laboratory (LPPT), Universitas 
Gadjah Mada, Yogyakarta. Rats were given 
anesthesia using an intramuscular dose of 
ketamine 30 mg/kg of body weight. Following 
after anesthesia, the hairs on the back were 
shaved after they were cleaned by using 10% 
povidone-iodine. The wound was created 
in the back area that was free of hair with a 
diameter of approximately two centimeters in 
full thickness (FIGURE 1). 
FIGURE 1. A: skin puncher; B: prepared and draped female rat; C: initial wound
Animal treatment
Eight rats were given a number from 
one to eight and randomly divided into two 
groups using the lottery method. In the first 
group as treatment group, the wound was 
compressed using sterile gauze moistened 
with 0.5 mg/mL of MMC for five minutes 
and rinsed with 10 mL of saline solution. The 
topical concentration value was adopted from 
the current literature.6 In the second group 
as control, the wound was compressed using 
sterile gauze moistened with saline solution 
without MMC for 5 minutes.
On the third day, the wound diameter was 
measured in both groups. We performed a 
necropsy on one of rats from each group; then 
we repeated the pretreatment for the rest of the 
rats in each group. On the 7th and 15th day, the 
wound skin diameters were measured in both 
groups. During the study, there were no sick or 
dead rats. The sample tissues were observed 
to notice any differences in the diameter of 
the wound, necrosis, scar formation and tissue 
color. This study was approved by the Ethical 
Committee of the Faculty of Medicine, Public 
Health, and Nursing, Universitas Gadjah 
Mada/Dr. Sardjito General Hospital under 
permit (KE/FK/594/EC/2015).
Statistical analysis
The wound skin diameters were analyzed 
by means of descriptive statistics following 
by visual and macroscopic analysis. 
RESULTS
The results show that the wound skin 
diameters decreased more slowly in rats 
given with MMC, suggesting that the healing 
process took a longer time compared to the 
rats that given with saline solution (FIGURE 
2 and TABLE 1).
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FIGURE 2. Groups of rats that received mitomycin-C (A: Day 0; B: day 3; C: day 7; D: day 15)
The formation of scar tissue in rats after 
MMC administration was smaller indicated 
by decreased scar tissue formation in 
chronic wounds. The rats after topical MMC 
administration showed a brownish color on the 
wound, and by day of 15 some of the lesions 
appeared to be black, dry, and hard, which 
were characteristics of the necrotic wounds. 
The rats after saline solution administration 
did not reveal any necrotic tissue. The 
wound consistency in rats after topical MMC 
administration appeared brownish and after 
15 days, coated by dark brown, dry, and hard 
brown tissue with surrounding tissue under 
local edema. The wound skin characteristics 
are shown in TABLE 1.
TABLE 1. The wound analysis based on wound diameter, scar formation, necrosis and wound consistency
Days Rats Wound Diameter (mm)
Scar 
formation Necrosis Wound consistency
Day-0 1 19.73 - - Red, moist
2 19.09 - - Red, moist
Day-3 3 19.00 - + Brownish, dry
4 19.00 + - Pink, moist
Day-7 5 16.16 - ++ Blackish brown, dry, thick
6 17.13 ++ - Pink, soft
Day-15 7 15.78 + +++ Blackish, hard
8 10.78 +++ - Slightly pale, soft
DISCUSSION
Our study showed that for the macroscopic 
parameters analyzed from the rats after topical 
MMCs administration was decreased in 
diameter of the wound, the fewer scar tissue 
formation and formed necrotic tissue, with hard 
consistency and blackish brown wounds. This 
results were in accordance with the previous 
studies which showed MMC administration 
topically in rats decreased wound strength and 
reduced scarring process  indicating a chronic 
wound healing occurred.6,8 However, the 
mechanism of MMC in inhibiting fibroblast 
proliferation remains unclear.
Wound healing process consists of 
three phases that overlap each other, namely 
inflammation, proliferation and remodeling.9-11 
After a skin injury, platelets are activated in 
the ruptured blood vessels and initiate clot 
formation to stop the bleeding. Platelets 
release a factor that stimulates the arrival of 
immune cells into the wound area of the blood 
circulation. Polymorphonuclear neutrophils 
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(PMN) come first, followed by monocytes 
that rapidly differentiate into macrophages. 
Neutrophils produce many reactive oxygen 
species (ROS), proteases and proinflammatory 
cytokines to clean wounds. When the process 
is over, neutrophils will undergo apoptosis 
and be phagocytosed by macrophages. 
Macrophages will also phagocyte bacteria 
and debris to clean wounds. When the wound 
is clean, the proliferation process will begin, 
which is the process of tissue growth. Cells in 
the wound area will proliferate and migrate to 
replace lost tissue. Some of the cells involved 
are the extracellular matrix (ECM) or also 
called granulation tissue, which contains 
keratinocytes. During the remodeling phase, 
the final phase of the wound healing process, 
the granulation tissue becomes mature, 
and its mechanical strength increases. The 
complete process of wound healing occurs 
when myofibroblast and vascular cells start to 
apoptosis, leaving scar tissue rich in collagen. 
In chronic wounds, the proliferative and 
remodeling phases are not yet fully initiated 
nor established so that the wound remains in 
the inflammatory phase. The absence of tissue 
regeneration causes the wound to be healed 
incompletely.7 Observations in this study were 
conducted on days 0, 3, 7, and 15 because the 
process of wound healing in rats is actually 
faster than humans. The rats only take about 
10-14 days to heal their wounds.12 Based on 
our observations, the macroscopic wound 
healing becomes slower as we predicted 
earlier.
Some examples of chronic wounds are 
diabetic ulcers, venous ulcers, and pressure 
ulcers. Microscopically, chronic wounds 
have many inflammatory cells infiltrated, 
mainly neutrophils. It is thought that the 
cause of the chronic wound healing process 
is that fibroblasts lose their migration 
capacity and become unresponsive to growth 
factor signals. This change is indicated by 
the decrease of TGF-β receptor levels and 
subsequent downward cascades in the wound 
healing process are disrupted. In previous 
studies, it was found that in chronic wounds, 
pro-inflammatory macrophages (M1) persist 
and did not transition into anti-inflammatory 
macrophages (M2), thus appeared to 
contribute to tissue repair disorders. The 
increased matrix of metalloproteinase (MMP) 
in chronic wounds is also thought to be the 
cause of decreased signaling and growth 
factor responsiveness. The process of re-
epithelization also becomes impeded by the 
decrease in the capacity of immune cells in 
chronic wounds, resulting in the buildup of 
debris cells.7,13
Formed scar tissues depend on the degree 
of fibrosis of the wound. The formation of 
fibrin during the hemostasis phase will be 
replaced by granulation tissue consisting of 
fibroblasts, macrophages and endothelial 
cells. Fibroblasts have an essential role in 
the wound healing process. Fibroblasts can 
synthesize collagen for an extracellular 
matrix useful as the foundation for epithelial 
cells and tissue epithelization. The study 
by Gray et al.14 reported that mitomycin-c 
has the ability to inhibit DNA synthesis to 
prevent the proliferation of fibroblasts in the 
long term. Experimental study on animals 
conducted by Lampus et al.15 reported that 
topical mitomycin-c was able to reduce total 
fibroblast in anoplasty wound healing trials in 
Wistar rats. Another study by Su et al.16 also 
shows the same result, finding topical MMC 
over 0.3 mg/mL can delay the wound healing 
via anti-cell proliferation effect and also that 
MMC inhibits angiogenesis of the wound 
via inhibition of vascular endothelial growth 
factor (VEGF).
The novelty of this study is that no 
macroscopic observation has been done with 
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necrotic variables and wound consistency in 
chronic wound-induced animal models using 
MMC in any previous study. Typically, in 
the past, the assessed variables were degree 
of fibrosis, vascular proliferation and wound 
strength.6
Although this study is preliminary, it has 
shown that the application of topical MMC 
to surgical wounds in the rats resulted in 
disrupted healing process. Our long-term 
aims that motivate this study are to make an 
ideal chronic wound animal model that could 
be used to study diseases that are linked with 
chronic wound healing such as diabetic, 
venous, and pressure ulcers. We also intend to 
evaluate the possible adverse effects that might 
be caused by topical MMC on chronic wound 
healing models using different concentrations 
and more prolonged exposure over extended 
periods of time. Further studies are needed 
to examine these important salutogenesis 
issues. However, our small sample size could 
not provide sufficient power for our results 
and consequently larger samples are needed 
to provide clarification and confirmation of 
better results. We recommend that further 
research with microscopic tissue examination 
be performed with clinical trials involving 
human subjects.
CONCLUSION
In conclusion, the MMC inhibits wound 
healing process on rat surgical wound model 
as indicated by the formation of less scarring 
and longer wound healing duration that seen 
from slower diameter reduction. In addition, 
the wound tissue appears dry, hard, thick, and 
the surface appears colored blackish.
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